KR20180132807A - 신경퇴행성 질환의 치료용 tdp-43 미토콘드리아 국소화 억제제 - Google Patents

신경퇴행성 질환의 치료용 tdp-43 미토콘드리아 국소화 억제제 Download PDF

Info

Publication number
KR20180132807A
KR20180132807A KR1020187031919A KR20187031919A KR20180132807A KR 20180132807 A KR20180132807 A KR 20180132807A KR 1020187031919 A KR1020187031919 A KR 1020187031919A KR 20187031919 A KR20187031919 A KR 20187031919A KR 20180132807 A KR20180132807 A KR 20180132807A
Authority
KR
South Korea
Prior art keywords
tdp
seq
mitochondrial
acid sequence
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187031919A
Other languages
English (en)
Korean (ko)
Inventor
싱롱 왕
Original Assignee
케이스 웨스턴 리저브 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 케이스 웨스턴 리저브 유니버시티 filed Critical 케이스 웨스턴 리저브 유니버시티
Publication of KR20180132807A publication Critical patent/KR20180132807A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epidemiology (AREA)
KR1020187031919A 2016-04-07 2017-04-07 신경퇴행성 질환의 치료용 tdp-43 미토콘드리아 국소화 억제제 Ceased KR20180132807A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662319580P 2016-04-07 2016-04-07
US62/319,580 2016-04-07
US201662328484P 2016-04-27 2016-04-27
US62/328,484 2016-04-27
PCT/US2017/026675 WO2017177178A1 (en) 2016-04-07 2017-04-07 Tdp-43 mitochondrial localization inhibitor for the treatment of neurodegenerative disease

Publications (1)

Publication Number Publication Date
KR20180132807A true KR20180132807A (ko) 2018-12-12

Family

ID=60000683

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187031919A Ceased KR20180132807A (ko) 2016-04-07 2017-04-07 신경퇴행성 질환의 치료용 tdp-43 미토콘드리아 국소화 억제제

Country Status (9)

Country Link
US (3) US11124553B2 (https=)
EP (1) EP3440094B1 (https=)
JP (1) JP2019513752A (https=)
KR (1) KR20180132807A (https=)
CN (1) CN109563130A (https=)
AU (1) AU2017248353A1 (https=)
CA (1) CA3020344A1 (https=)
SG (1) SG11201808829VA (https=)
WO (1) WO2017177178A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220040945A (ko) 2020-09-24 2022-03-31 재단법인대구경북과학기술원 Ｈｄａｃ６의 ｔｄｐ－４３ 단백질병증 예방 또는 치료제로서의 용도
WO2024181693A1 (ko) * 2023-02-28 2024-09-06 (주)케어젠 펩타이드 복합체를 유효성분으로 포함하는 항노화용 조성물
KR20250016616A (ko) 2023-07-20 2025-02-04 충북대학교 산학협력단 ｃ­Ａｂｌ에 의한 ＴＤＰ­４３의 특이적 인산화 분석을 통한 신경퇴행성 질환을 진단하는 방법 및 이를 이용한 신경퇴행성 질환의 치료제 스크리닝 방법
WO2026019137A1 (ko) * 2024-07-19 2026-01-22 재단법인대구경북과학기술원 디히드로코스투스 락톤을 유효성분으로 포함하는 육종 융합 단백질 또는 티디피 사십삼 관련 질환의 예방 또는 치료용 조성물

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10906949B2 (en) 2017-06-28 2021-02-02 The Cleveland Clinic Foundation Methods of treating spinal cord injury using a chondroitin sulfate proteoglycan (CSPG) reduction peptide (CRP) comprising a cell membrane penetrating domain, a CSPG binding domain, and a lysosome targeting domain
CN113683703B (zh) * 2020-05-18 2023-08-15 中国人民解放军陆军军医大学第二附属医院 一种hTERT靶向物及其用途
WO2021247893A1 (en) * 2020-06-03 2021-12-09 Yumanity Therapeutics, Inc. Bicyclic heteroaromatic amide compounds and uses thereof
US20230250094A1 (en) * 2020-07-15 2023-08-10 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of tdp-43 activity and uses thereof
CN114057858B (zh) 2020-08-10 2023-03-21 上海瑞吉康生物医药有限公司 对引起神经变性和神经退行性疾病的蛋白聚集具有解聚作用的多肽
JP6961278B1 (ja) * 2021-03-10 2021-11-05 国立研究開発法人量子科学技術研究開発機構 生体試料中のｔｄｐ−４３を測定する方法及び装置
CN113450336B (zh) * 2021-07-01 2022-10-25 维柯基科技(上海)有限公司 一种多孔荧光微阵列图像的处理方法、装置、计算机设备及计算机可读存储介质
WO2025152803A1 (zh) * 2024-01-17 2025-07-24 四川大学 一种靶向traf6的多肽及其用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US5670617A (en) 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
IE913929A1 (en) 1990-11-13 1992-05-20 Immunex Corp Bifunctional selectable fusion genes
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5858683A (en) * 1996-08-30 1999-01-12 Matritech, Inc. Methods and compositions for the detection of cervical cancer
GB9718609D0 (en) 1997-09-02 1997-11-05 Imp College Innovations Ltd Fusion protein
GB9723824D0 (en) * 1997-11-11 1998-01-07 Actinova Ltd Cytostatic agents
US6841535B2 (en) 2000-07-31 2005-01-11 Active Motif Peptide-mediated transfection agents and methods of use
US20040229837A1 (en) * 2003-05-15 2004-11-18 Yijuang Chern Treatment of neurodegenerative diseases
CA2613749A1 (en) * 2005-07-01 2007-01-11 Arbor Vita Corporation Methods and compositions for diagnosis and treatment of viral and bacterial infections
CA2671410C (en) * 2006-12-06 2016-11-22 Thomas Jefferson University Peptide and treatment for hiv-1 infection
JP5798322B2 (ja) * 2008-02-01 2015-10-21 ワシントン ユニバーシティ イン セント ルイス Ｔｄｐ−４３蛋白質症に関連した配列およびその使用法
WO2010072228A1 (en) * 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
US9926353B2 (en) * 2011-07-19 2018-03-27 New York University Immunotherapeutic modulation of amyloidogenic disease using non-fibrillogenic, non-amyloidogenic polymerized proteins and peptides
EP2821504A4 (en) * 2012-02-28 2016-02-17 Univ Tokyo Nat Univ Corp METHOD FOR DETERMINING A DISEASE RELATED TO TDP-43 CONCENTRATION IN CELLS
US9017672B2 (en) * 2012-05-11 2015-04-28 Immunicum Aktiebolag Hexon Tat-PTD modified adenovirus and uses thereof
WO2013192298A1 (en) * 2012-06-22 2013-12-27 The Scripps Research Institute Apoptosis biomarkers
GB201408255D0 (en) * 2014-05-09 2014-06-25 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220040945A (ko) 2020-09-24 2022-03-31 재단법인대구경북과학기술원 Ｈｄａｃ６의 ｔｄｐ－４３ 단백질병증 예방 또는 치료제로서의 용도
WO2024181693A1 (ko) * 2023-02-28 2024-09-06 (주)케어젠 펩타이드 복합체를 유효성분으로 포함하는 항노화용 조성물
KR20250016616A (ko) 2023-07-20 2025-02-04 충북대학교 산학협력단 ｃ­Ａｂｌ에 의한 ＴＤＰ­４３의 특이적 인산화 분석을 통한 신경퇴행성 질환을 진단하는 방법 및 이를 이용한 신경퇴행성 질환의 치료제 스크리닝 방법
WO2026019137A1 (ko) * 2024-07-19 2026-01-22 재단법인대구경북과학기술원 디히드로코스투스 락톤을 유효성분으로 포함하는 육종 융합 단백질 또는 티디피 사십삼 관련 질환의 예방 또는 치료용 조성물

Also Published As

Publication number Publication date
US20220220173A1 (en) 2022-07-14
AU2017248353A1 (en) 2018-10-25
CA3020344A1 (en) 2017-10-12
CN109563130A (zh) 2019-04-02
EP3440094A1 (en) 2019-02-13
SG11201808829VA (en) 2018-11-29
US20190211070A1 (en) 2019-07-11
US11124553B2 (en) 2021-09-21
JP2019513752A (ja) 2019-05-30
WO2017177178A1 (en) 2017-10-12
US12129285B2 (en) 2024-10-29
EP3440094B1 (en) 2021-02-17
EP3440094A4 (en) 2019-03-20
US20260116935A1 (en) 2026-04-30

Similar Documents

Publication Publication Date Title
US12129285B2 (en) TDP-43 mitochondrial localization inhibitor for the treatment of neurogenerative disease
JP6203215B2 (ja) プロミニン−１ペプチド断片およびその使用
AU2010362444B2 (en) Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
DK2627346T3 (en) Cell permeable peptide inhibitors of the JNK signal transduction pathway for use in the treatment of uveitis
CN108431021A (zh) 具有神经元损失预防和再生效果的肽以及包含该肽的组合物
JP6046493B2 (ja) プロミニン−１の血管新生促進フラグメントおよびその使用
KR20150128731A (ko) 누트린-3a 및 펩티드에 의한 폐 섬유증의 저해
US20180327458A1 (en) Pharmaceutical compositions for prevention or treatment of neurodegenerative diseases
KR20190137786A (ko) 뇌 오스테오칼신 수용체 및 인지 장애
JP2010239971A (ja) 細胞におけるペルオキシソームカタラーゼ機能の促進
US10258672B2 (en) Compositions and methods of treating root avulsion injury
US20200230207A1 (en) Treatment of bone growth disorders
KR102772298B1 (ko) 미엘린 장애의 치료를 위한 조성물 및 방법
JP2004508827A (ja) カルシウム結合タンパク質
US8778884B2 (en) Glioprotectant peptide for use in the treatment of amyotrophic lateral sclerosis (ALS) and methods related thereto
US20240392279A1 (en) Modified protein disulfide isomerase and uses thereof
US11136362B2 (en) Peptide modulators of specific calcineurin protein-protein interactions
JP2008530029A (ja) 神経保護剤およびそれらの使用方法
US20210290727A1 (en) MODULATION OF mTORCI ACTIVITY AND AUTOPHAGY VIA CIB2-RHEB INTERACTION
JPWO2006006337A1 (ja) 神経疾患の予防又は治療薬

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20181102

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200401

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210927

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20211203

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20210927

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I